Asset profile
Pirtobrutinib
Small molecule
—no evidence
Evidence outlook
No featureable registry evidence
The studies registered under this drug are withdrawn, terminated, post-marketing only, or belong to other products, so none can represent its own clinical progression.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 23 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Pirtobrutinib: this drug | Phase 3 | Small molecule | BTK | ||
| Rilzabrutinib | Phase 3 | Small molecule | BTK | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Ixazomib | Approved | Small molecule | Proteasome | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Melphalan Flufenamide | Approved | Small molecule | DNA (alkylation), delivered via aminopeptidase-mediated intracellular activation |
…and 46 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(45 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
November 2026 (2)
December 2026 (1)
Phase 2Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06466122 · CT.gov ↗
What to watch
2027 (9)
February 2027 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-02-28 · NCT06522386 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic MalignancyRecruiting
Est. primary completion 2027-04-28 · NCT05529069 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaRecruiting
Est. primary completion 2027-07-01 · NCT06333262 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, PirtobrutinibNot yet recruiting
Est. primary completion 2027-07-30 · NCT07744737 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZLNot yet recruiting
Est. primary completion 2027-08-31 · NCT07744750 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic LymphomaRecruiting
Est. primary completion 2027-10 · NCT05254743 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Lymphoma, Mantle-CellActive not recruiting
Est. primary completion 2027-11 · NCT04662255 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome …Active not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07685717 · CT.gov ↗
What to watch
2028 (17)
January 2028 (1)
Phase 2Chronic Lymphocytic Leukemia, Richter's TransformationRecruiting
Est. primary completion 2028-01-15 · NCT06043674 · CT.gov ↗
What to watch
February 2028 (2)
April 2028 (2)
June 2028 (2)
July 2028 (3)
Phase 1Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt LymphomaRecruiting
Est. primary completion 2028-07 · NCT05990465 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, PirtobrutinibNot yet recruiting
Est. primary completion 2028-07-31 · NCT07744724 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-07-31 · NCT06252675 · CT.gov ↗
What to watch
August 2028 (2)
September 2028 (2)
October 2028 (1)
Phase 2Mantle Cell Lymphoma (MCL)Not yet recruiting
Est. primary completion 2028-10-30 · NCT07684950 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT07052695 · CT.gov ↗
What to watch
Phase 2PCNSL, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT07350850 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 2Waldenstrom MacroglobulinemiaActive not recruiting
Est. primary completion 2029-01-25 · NCT05734495 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-05 · NCT06812715 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-08 · NCT06553872 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaRecruiting
Est. primary completion 2029-10 · NCT07516093 · CT.gov ↗
What to watch
2030 (5)
February 2030 (1)
Phase 1Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)Recruiting
Est. primary completion 2030-02-01 · NCT07428707 · CT.gov ↗
What to watch
May 2030 (4)
Phase 2Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell LymphomaActive not recruiting
Est. primary completion 2030-05 · NCT07162181 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic Leukemia, Non-Hodgkin LymphomaRecruiting
Est. primary completion 2030-05 · NCT06876649 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic Leukemia, Non-Hodgkin LymphomaRecruiting
Est. primary completion 2030-05 · NCT06876662 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic Leukemia, Lymphoma, Small LymphocyticRecruiting
Est. primary completion 2030-05 · NCT07218341 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 2Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)Recruiting
Est. primary completion 2031-06-01 · NCT06967610 · CT.gov ↗
What to watch
July 2031 (1)
Phase 2Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma …Recruiting
Est. primary completion 2031-07-31 · NCT06948786 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Marginal Zone LymphomaRecruiting
Est. primary completion 2031-12 · NCT06390956 · CT.gov ↗
What to watch
2032 (2)
2034 (1)
November 2034 (1)
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2034-11 · NCT07548450 · CT.gov ↗
What to watch
2035 (1)
October 2035 (1)
Phase 3Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma …Not yet recruiting
Est. primary completion 2035-10-01 · NCT07220187 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.